TICKERNERD
Menu
COLLCOLLHealthcare · Drug Manufacturers - Specialty & Generic

COLL Stock Forecast: Collegium Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$23
−0.74% on the day

The 7 Wall Street analysts covering Collegium Pharmaceutical, Inc. hold a median 12-month price target of $48 — +111.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$705.2M
Ticker Nerd rank
74 / 100
Median analyst target
$48
Analysts covering
7
Revenue$199.9M+6.3% y/y
Operating income$3.7M
Net income−$15.1M
Free cash flow$70.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.0%
1M
−12.4%
YTD
−50.9%
1Y
−41.8%
From 52W high
−54.4%
From 52W low
0.0%
$23
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COLL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Collegium Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
95
Volatility
92
Growth
87
Accruals
64
Size
49
Revisions
40
Issuance
31
Momentum
21

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COLL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COLL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26COLLHigh $60Median $48Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $43Median $48High $60

The green dot is the last close — the median target sits +111.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
9 Sept 2026Leerink PartnersInitiatesOutperform$45
9 Sept 2026Truist SecuritiesMaintainsBuy$58 → $49
19 Aug 2026BarclaysMaintainsOverweight$56 → $48
19 Aug 2026BarclaysMaintainsOverweight—
7 Aug 2026Piper SandlerReiteratesNeutral$45 → $43
7 Aug 2026Piper SandlerReiteratesNeutral—
6 Aug 2026NeedhamMaintainsBuy—
6 Aug 2026NeedhamMaintainsBuy$56 → $46
20 Mar 2026HC Wainwright & Co.ReiteratesBuy$60
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026NeedhamReiteratesBuy$54 → $56
19 Mar 2026NeedhamReiteratesBuy—
26 Feb 2026NeedhamMaintainsBuy—
9 Jan 2026BarclaysMaintainsOverweight—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
8 Jan 2026NeedhamMaintainsBuy—
9 Dec 2025BarclaysInitiatesOverweight—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2025Truist SecuritiesMaintainsBuy—
28 Oct 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COLL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COLL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Collegium Pharmaceutical, Inc. returned −41.8% against +17.5% for the S&P 500, dividends included.

COLL vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26COLLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COLL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.3%
Analysts raising
0
Analysts cutting
4
Fundamentals

Collegium Pharmaceutical, Inc. (COLL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.1×

Cheaper than 40% of US stocks

Price / sales
0.9×

Cheaper than 72% of US stocks

Price / book
2.4×

Cheaper than 40% of US stocks

EV / EBITDA
4.5×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
6.3%

Higher than 42% of US stocks

Earnings growth (YoY)
6.3%

Higher than 43% of US stocks

Gross margin
55.2%

Higher than 68% of US stocks

Operating margin
5.7%

Higher than 56% of US stocks

Net margin
5.9%

Higher than 62% of US stocks

Returns & dividend
Return on equity
17.6%

Higher than 78% of US stocks

Return on assets
5.8%

Higher than 80% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Collegium Pharmaceutical, Inc. (COLL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Collegium Pharmaceutical, Inc. has a market value of $705.2M and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $808.2M. The latest quarter grew 6.3% year on year.

  • Net income over the same four quarters: $47.9M, a 5.9% net margin.

  • Diluted earnings per share, trailing twelve months: $1.24.

  • Free cash flow in the twelve months to 30 June 2026: $328.3M.

  • Shares outstanding: 32.5M.

  • Trailing P/E: 18.1×; forward P/E: 3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Collegium Pharmaceutical, Inc. employs 423 people — $1.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

COLL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
COLLCollegium Pharmaceutical, Inc.$705.2M
74
IRWDIronwood Pharmaceuticals, Inc.$665.3M
100
GLASGlass House Brands, Inc.$656.6M
43
AQSTAquestive Therapeutics, Inc.$599.9M
53
TLRYTilray Brands, Inc.$547.5M
18
EOLSEvolus, Inc.$510.1M
88
PCRXPacira Biosciences, Inc.$1.0B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Collegium Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COLL news & analysis

Collegium to Participate in Upcoming Investor Conferences

GlobeNewsWire · 8 Sept 2026neutral

Collegium Pharmaceutical announced that its management will participate in several upcoming investor conferences. The company, which focuses on improving the lives of people living with serious and often misunderstood conditions, made the announcement on September 8, 2026.

Why it matters — COLL watchers would care because management's participation in investor conferences signals ongoing investor engagement and potential visibility for the company.

Collegium Announces $50 Million Accelerated Share Repurchase Program

GlobeNewsWire · 13 Aug 2026positive

Collegium Pharmaceutical announced it entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Following completion, $100 million will remain under the program.

Why it matters — The buyback signals the company's ongoing capital-return activity under its authorized repurchase program, which may be of interest to stockholders tracking share count and capital allocation.

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Collegium Pharmaceutical, Inc.'s Q2 2026 earnings call. The content consists of the call's headline and transcript listing with no additional detail provided.

Why it matters — A COLL watcher would care because the transcript represents the company's official second-quarter earnings call communication.

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 6 Aug 2026neutral

Collegium Pharmaceutical reported its earnings for the quarter ended June 2026. The article examines how the company's revenue, EPS, and other key metrics compare with Wall Street estimates and year-ago figures.

Why it matters — A COLL watcher would care because this review shows how the company's actual quarterly performance stacked up against analyst expectations and prior-year results.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Collegium Pharmaceutical reported Q2 earnings of $1.92 per share, surpassing the Zacks Consensus Estimate of $1.68 per share. This matches the earnings per share of $1.68 recorded in the same quarter a year ago.

Why it matters — A COLL watcher would note that the company exceeded analyst earnings expectations for the quarter, indicating stronger-than-anticipated performance.

FAQ

Frequently asked questions about COLL stock

What is the COLL stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Collegium Pharmaceutical, Inc. have a median 12-month price target of $48, with estimates ranging from $43 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COLL stock a buy right now?

Of the 7 analysts covering Collegium Pharmaceutical, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Collegium Pharmaceutical, Inc. 74 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COLL?

As at 12 Sept 2026, Collegium Pharmaceutical, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will COLL stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +111.0% from the last close, and Ticker Nerd's factor model ranks Collegium Pharmaceutical, Inc. 74 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COLL stock forecast for 2030?

No analyst covering Collegium Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $60 over the next 12 months.

How has COLL stock performed over the past year?

Collegium Pharmaceutical, Inc. returned -41.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Collegium Pharmaceutical, Inc. do?

Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD).

What is the latest news on COLL?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Collegium to Participate in Upcoming Investor Conferences". Collegium Pharmaceutical announced that its management will participate in several upcoming investor conferences. The company, which focuses on improving the lives of people living with serious and often misunderstood conditions, made the announcement on September 8, 2026.

Company

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.

CEO Mr. Vikram Karnani · 423 employees · United States · https://www.collegiumpharma.com